AURX News

Nuo Therapeutics, which markets a medical system for chronic wound care, withdrew its plans for an initial public offering on Friday, citing market conditions. It had filed to raise $11 million by offering 2.1 million shares at a price range of $4.50 to $5.50. Its proposed post-IPO market cap was below $50 million, and therefore did not meet our IPO tracking stats. The...read more

Audeo Oncology, which is developing a combination therapy in Phase 3 trial for metastatic colorectal cancer, withdrew its plans for an initial public offering on Friday. The company had launched its deal in November 2012 but ultimately postponed its offering in December 2012. The San Francisco, CA-based company was founded in 2006. Leerink Partners and Oppenheimer & Co. were...read more

Audeo Oncology, which is developing a combination therapy in Phase 3 trial for metastatic colorectal cancer, postponed its IPO on Thursday, citing poor market conditions. The San Francisco, CA-based company was founded in 2006 and has yet to generate product revenue. Leerink Swann and Oppenheimer & Co. were set to be the joint bookrunners on the deal....read more

The following IPOs are expected to price this week:

Audeo Oncology (AURX), which is developing a combination therapy in Phase 3 trial for metastatic colorectal cancer, plans to raise $49 million by offering 3.3 million shares at a price range of $14.00 to $16.00. At the midpoint of the...read more